Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Bought by Artemis Investment Management LLP

Artemis Investment Management LLP raised its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO) by 484.5% during the first quarter, Holdings Channel reports. The institutional investor owned 88,031 shares of the medical research company’s stock after buying an additional 72,971 shares during the period. Artemis Investment Management LLP’s holdings in Thermo Fisher Scientific were worth $43,804,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also made changes to their positions in TMO. Bernard Wealth Management Corp. acquired a new position in Thermo Fisher Scientific in the fourth quarter valued at $25,000. Pillar Financial Advisors LLC acquired a new stake in shares of Thermo Fisher Scientific in the fourth quarter valued at approximately $29,000. Ameriflex Group Inc. purchased a new position in shares of Thermo Fisher Scientific during the fourth quarter worth approximately $30,000. Noble Wealth Management PBC purchased a new stake in Thermo Fisher Scientific in the 4th quarter valued at $35,000. Finally, Cassady Schiller Wealth Management LLC grew its position in Thermo Fisher Scientific by 89.2% during the 4th quarter. Cassady Schiller Wealth Management LLC now owns 70 shares of the medical research company’s stock worth $36,000 after purchasing an additional 33 shares during the last quarter. 89.23% of the stock is owned by institutional investors and hedge funds.

Thermo Fisher Scientific Stock Performance

NYSE TMO opened at $412.02 on Friday. The company has a quick ratio of 1.38, a current ratio of 1.77 and a debt-to-equity ratio of 0.64. The stock has a market cap of $155.53 billion, a price-to-earnings ratio of 24.17, a price-to-earnings-growth ratio of 2.17 and a beta of 0.78. Thermo Fisher Scientific Inc. has a fifty-two week low of $385.46 and a fifty-two week high of $627.88. The business has a fifty day moving average of $410.11 and a 200-day moving average of $484.47.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings results on Wednesday, April 23rd. The medical research company reported $5.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.10 by $0.05. The company had revenue of $10.36 billion for the quarter, compared to analysts’ expectations of $10.23 billion. Thermo Fisher Scientific had a net margin of 15.19% and a return on equity of 17.15%. The firm’s revenue for the quarter was up .2% compared to the same quarter last year. During the same period last year, the company earned $5.11 EPS. As a group, analysts predict that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, July 15th. Stockholders of record on Friday, June 13th will be given a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.42%. The ex-dividend date is Friday, June 13th. Thermo Fisher Scientific’s dividend payout ratio is currently 10.09%.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on TMO shares. Barclays decreased their target price on shares of Thermo Fisher Scientific from $475.00 to $450.00 and set an “equal weight” rating for the company in a research note on Tuesday. UBS Group dropped their price objective on shares of Thermo Fisher Scientific from $715.00 to $500.00 and set a “buy” rating on the stock in a research note on Thursday, April 24th. The Goldman Sachs Group set a $610.00 target price on shares of Thermo Fisher Scientific and gave the company a “buy” rating in a report on Wednesday, April 23rd. Wells Fargo & Company reduced their price objective on shares of Thermo Fisher Scientific from $580.00 to $570.00 and set an “overweight” rating for the company in a research report on Thursday, April 24th. Finally, Evercore ISI dropped their target price on Thermo Fisher Scientific from $585.00 to $500.00 and set an “outperform” rating on the stock in a research report on Thursday, April 24th. Four investment analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company. According to MarketBeat, Thermo Fisher Scientific presently has a consensus rating of “Moderate Buy” and a consensus price target of $604.05.

Insider Buying and Selling

In other news, EVP Gianluca Pettiti sold 300 shares of the stock in a transaction dated Monday, April 28th. The shares were sold at an average price of $429.93, for a total transaction of $128,979.00. Following the transaction, the executive vice president now directly owns 23,167 shares in the company, valued at $9,960,188.31. This represents a 1.28% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. 0.33% of the stock is currently owned by company insiders.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.